For example, around 15- 20% of patients with prostate cancer lack the tumour suppressor gene PTEN, which result in disease that is difficult to treat. PTEN serves largely as a biomarker of ...

We have used the SV-40 based TRAMP model of prostate cancer to explore the role of FGF2 and the PTEN tumor suppressor gene in prostate cancer progression. To accomplish this we crossed TRAMP mice to ...

Previous research has shown that this pathway, called the PI3K-AKT pathway, is frequently mutated in prostate cancer. Although the most common mutation, in a gene called Pten, had already been ...

Estimates for the frequency of PTEN mutations in prostate cancer vary widely, between around 15% and 60%, depending on the type and stage of the disease, but testing for the biomarker isn't ...

For example, advanced prostate cancer (PCa) is often linked to changes in the activity of a tumor suppressor, called phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and a widely ...

UK-based pharmaceutical company AstraZeneca has reported positive results from its Phase III CAPItello-281 trial, which evaluated Truqap combined with abiraterone and androgen deprivation therapy ...

For example, advanced prostate cancer (PCa) is often linked to changes in the activity of a tumor suppressor, called phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and a widely ...

including the IPATunity-170 trial in triple-negative breast cancer and IPATunity-130 in hormone receptor-positive, HER2-negative, and PTEN-mutated breast cancer. So far, no AKT inhibitors have ...